| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 04/02/2002 | US6365749 Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| 04/02/2002 | US6365736 Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals |
| 04/02/2002 | US6365714 Amino acid sequence of a polypeptide; antiinflammatory agents; antiproliferative agents; antiapoptotic agents |
| 04/02/2002 | US6365664 Gels formed by the interaction of poly(aldehyde) with various substances |
| 04/02/2002 | US6365594 As opioid agonists and antagonists and are useful as i.a. analgesics |
| 04/02/2002 | US6365587 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 04/02/2002 | US6365584 For prophylaxis and therapy of inflammatory and/or allergic diseases, lung fibrosis, fibrosing alveolitis and scarring, collagenoses such as lupus erythematodes and sclerodermia as well as arteriosclerosis, psoriasis and neoplasm |
| 04/02/2002 | US6365583 Methods to enhance white blood cell count |
| 04/02/2002 | US6365572 For therapy of diseases related to increased or unwanted synthesis of basement membranes such as diabetes mellitus; atherosclerosis; cancer; diabetic retinopathia; fibroplasia retrolentalis; or psoriasis, rheumatoic arthritis |
| 04/02/2002 | US6365391 Isolated human serine protease, nucleic acid molecules encoding human serine protease, and uses thereof |
| 04/02/2002 | US6365389 Human protein kinase H2LAU20 |
| 04/02/2002 | US6365370 Dna which codes for 5-hydroxytryptamine 3-c protein of defined amino acid sequence; antiinflammatory agents; treatment of huntington's disease, alzheimer's disease and others |
| 04/02/2002 | US6365365 Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
| 04/02/2002 | US6365180 Oral liquid compositions |
| 04/02/2002 | CA2357961A1 Method for reduction of inflammation and erythema |
| 04/02/2002 | CA2357925A1 Prophylactic use of n-methyl-d-asparate (nmda) antagonists |
| 04/02/2002 | CA2099868C Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines |
| 04/02/2002 | CA2056066C A physical form of n-[4-[5-(cyclopentyloxycarbony)amino-1-methylindol-3yl-methy1]-3-methoxybenzoy1]-2-methlbenzenesulphonamide, processes for its preparation and compositions containing it |
| 04/02/2002 | CA2051012C Carbocyclic adenosine analogs useful as immunosupressants |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024909A2 Receptor nucleic acids and polypeptides |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024727A2 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | WO2002024715A2 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 03/28/2002 | WO2002024711A1 Novel thiazole bicyclic compounds |
| 03/28/2002 | WO2002024710A1 Tricyclic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (mmp) inhibitors |
| 03/28/2002 | WO2002024706A2 Water soluble rapamycin esters |
| 03/28/2002 | WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | WO2002024697A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 03/28/2002 | WO2002024693A1 A process for producing 3,4-dihydro naphthyridinone analogs |
| 03/28/2002 | WO2002024681A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 03/28/2002 | WO2002024680A1 Imidazole derivatives as raf kinase inhibitors |
| 03/28/2002 | WO2002024679A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY |
| 03/28/2002 | WO2002024674A1 Benzoic acid derivatives and uses thereof |
| 03/28/2002 | WO2002024673A1 Tetrahydrofuran derivatives and their use as nk-1 antagonists |
| 03/28/2002 | WO2002024665A1 Arylalkane-sulfonamides having endothelin-antagonist activity |
| 03/28/2002 | WO2002024659A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists |
| 03/28/2002 | WO2002024658A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | WO2002024657A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | WO2002024651A1 A process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024639A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | WO2002024636A2 N-acylsulfonamide apoptosis promoters |
| 03/28/2002 | WO2002024629A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | WO2002024613A2 Resorcinol derivatives |
| 03/28/2002 | WO2002024229A1 Method of regulating osteoclast formation |
| 03/28/2002 | WO2002024228A1 Method of regulating osteoclast formation |
| 03/28/2002 | WO2002024217A1 Use of il-8 protein modulators in the treatment of viral infections |
| 03/28/2002 | WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 03/28/2002 | WO2002024206A1 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| 03/28/2002 | WO2002024200A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | WO2002024194A2 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | WO2002024192A1 Dipeptide ligands of the npff receptor for treating pain and hyperalgesia |
| 03/28/2002 | WO2002024190A1 Use of r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature |
| 03/28/2002 | WO2002024185A2 Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 03/28/2002 | WO2002024162A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | WO2002024146A2 Methods of decreasing or preventing pain using spicamycin derivatives |
| 03/28/2002 | WO2002004624A9 Novel g protein-coupled receptor protein and dna thereof |
| 03/28/2002 | WO2002000679A3 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group |
| 03/28/2002 | WO2001096336A3 6,5-fused bicyclic heterocycles |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001083434A3 P-(sulfonyl)-aryl and heteroaryls amines |
| 03/28/2002 | WO2001077150A3 Serine-threonine kinase |
| 03/28/2002 | WO2001072279A3 Medical emulsion for lubrication and delivery of drugs |
| 03/28/2002 | WO2001066124A3 Composition for the treatment of heart failure |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001062793A3 Estrogen receptor beta variants and methods of detection thereof |
| 03/28/2002 | WO2001052825A3 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 03/28/2002 | WO2001045686A3 Formulations of adenosine a1 agonists |
| 03/28/2002 | WO2001039758A3 Method for the treatment and/or prophylaxis of diseases caused by il-12 using thalidomide and anti-inflammatory cytokine |
| 03/28/2002 | WO2001038552A3 Excipient system that contains coating substances with enzymatically removable side-groups |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2001023377A9 Polymorphic salt |
| 03/28/2002 | WO2001022955A2 Novel combination of loteprednol and antihistamines |
| 03/28/2002 | WO2001007405A3 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 03/28/2002 | WO2000066102A3 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | WO2000047231A9 Novel antisense inhibition of rad51 |
| 03/28/2002 | US20020038469 Delayed progression to aids by a missense allele of the ccr2 gene |
| 03/28/2002 | US20020038030 For therapy of inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's |
| 03/28/2002 | US20020038028 For therapy of neurological and psychological disorders are claimed. |
| 03/28/2002 | US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/28/2002 | US20020037926 And gabapentin and/or pregabalin or their salts to prevent or ameliorate chronic pain or convulsions; synergistic |
| 03/28/2002 | US20020037919 Compositions and methods of paclitaxel for preventing psoriasis |
| 03/28/2002 | US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases |
| 03/28/2002 | US20020037909 Enamine derivatives |
| 03/28/2002 | US20020037900 Hydroxamic acid derivatives |
| 03/28/2002 | US20020037897 Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037893 Heteroaryl diazabicycloalkanes, their preparation and use |
| 03/28/2002 | US20020037889 Imidazolidin-2-one derivatives; inhibiting bone resorption, vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, arthritis, viral disease, cancer and metastatic tumor growth |
| 03/28/2002 | US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/28/2002 | US20020037859 Antiarthritic agents; antiinflammatory agents |
| 03/28/2002 | US20020037852 Anticarcinogenic agents |
| 03/28/2002 | US20020037836 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| 03/28/2002 | US20020037572 Novel mammalian secreted group III phospholipase A2 |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037523 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of nervous system, autoimmune, inflammation, glomerulonephritis and osteoporosis disorders |
| 03/28/2002 | US20020037518 Polypeptide for use in the diagnosis, prevention and treatment of cell proliferation and inflammation defects |